Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.71 |
| ▸ | AGXT | P21549 | 2/20 | 0.71 |
| ▸ | MAOB | P27338 | 7/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710547 | 0.92 | MAOB (0.71) | IDO1AGXTMAOBABCB1HTR1A | |
| SCHEMBL11590273 | 0.89 | IDO1 (0.59) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL3768643 | 0.87 | IDO1 (0.71) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL20795337 | 0.87 | IDO1 (0.55) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL10820376 | 0.84 | MAOB (0.67) | MAOBABCB1 | |
| SCHEMBL487468 | 0.84 | IDO1 (0.48) | IDO1AGXTMAOB | |
| SCHEMBL8583458 | 0.83 | IDO1 (0.53) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL1144902 | 0.83 | IDO1 (0.67) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL27886344 | 0.83 | IDO1 (0.67) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL3389080 | 0.83 | IDO1 (0.67) | IDO1AGXTMAOBTAAR1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164991-A | Preparation method of aminopyrimidino pyrazole/pyrrole derivative | 四川大学华西医院 | 2024-06-11 | — | — | CN | claimed |
| CN-117886540-A | Preparation method of concrete segregation-resistant agent and segregation-resistant agent | 四川庄大混凝土有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| CN-100503798-C | Household product | TAKASAGO PERFUMERY CO LTD (JP) | 2009-06-24 | — | — | CN | claimed |
| CN-1730637-A | Household product | TAKASAGO PERFUMERY CO LTD (JP) | 2006-02-08 | — | — | CN | claimed |
| CN-118164991-A | Preparation method of aminopyrimidino pyrazole/pyrrole derivative | 四川大学华西医院 | 2024-06-11 | — | — | CN | disclosed |
| CN-114763312-B | Method for inducing H halogenation in C-H on benzene ring or heterocycle through ultraviolet light | 中国科学院大连化学物理研究所 | 2024-06-07 | — | — | CN | disclosed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| CN-117886540-A | Preparation method of concrete segregation-resistant agent and segregation-resistant agent | 四川庄大混凝土有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117886540-A | Preparation method of concrete segregation-resistant agent and segregation-resistant agent | 四川庄大混凝土有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-112912390-B | GLP-1 analogues and methods of preparation | 北京费森尤斯卡比医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117098670-A | Thermosensitive recording medium | 日本制纸株式会社 | 2023-11-21 | — | — | CN | disclosed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1475374-A1 | THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-4195178-A | Methylenecyclopentane derivatives | THE UPJOHN COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-4181798-A | Methylenecyclopentane derivatives | THE UPJOHN COMPANY (US) | 1980-01-01 | — | — | US | disclosed |
| US-4175202-A | 4,5,6-Trinor-3,7,-inter-m-phenylene prostaglandin A1 analogs | THE UPJOHN COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4084058-A | HYPOTENSIVES, ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | IDO1 2233/4885AGXT 3226/4885MAOB 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.